CBER’s Marks Says US FDA’s Rare Disease Work Expected To Win Trump Administration Support

Center for Biologics Evaluation and Research Director Peter Marks expects no fundamental changes in support for FDA initiatives and said the Rare Disease Innovation Hub, which promotes cross-center collaboration, is “consistent with what we're hearing in the current environment.”

Windsock
The FDA's Peter Marks hopes the support for rare disease drug development continues. (Shutterstock)

More from Cell & Gene Therapies

More from Rare Diseases